This Hedge Fund-Backed Biopharma Company Is Still Trying to Go Public

Zentalis set terms for its offering but warns that Covid-19 could set back many crucial developments for the company.

Stephen Taub March 31, 2020

Andreas Halvorsen, CEO of Viking Global.

(David Paul Morris/Bloomberg)

A fledgling biopharma company with heavy hedge fund backing is seemingly moving forward with its initial public offering, despite the stock market’s sharp selloff and overall volatility and growing concern that the Covid-19 virus is spreading throughout the United States.On Friday Renaissance Capital, an IPO

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.12.03 build:2025-12-12 Login